Related Experiment Video

Updated: May 13, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

[Effects of EGFR gene polymorphisms on efficacy and prognosis in advanced non-small cell lung cancer treated with

Liangshan Da1, Lin Xu

  • 1Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|March 22, 2013
PubMed

Insights

Epidermal growth factor receptor (EGFR) gene polymorphisms may predict treatment efficacy for advanced non-small cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors (TKIs). This review explores the link between EGFR polymorphisms and TKI treatment outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacogenomics

Background:

  • Advanced non-small cell lung cancer (NSCLC) treatment increasingly utilizes epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
  • Patient response to EGFR-TKIs varies significantly, necessitating improved predictive biomarkers beyond EGFR mutation detection.
  • Current EGFR mutation detection methods face limitations including tissue accessibility, technical complexity, and cost.

Purpose of the Study:

  • To review the correlation between epidermal growth factor receptor (EGFR) gene polymorphisms and the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC).
  • To explore the potential of EGFR gene polymorphisms as predictive biomarkers for EGFR-TKI therapy in advanced NSCLC.

Main Methods:

  • Literature review of studies investigating EGFR gene polymorphisms and their association with clinical outcomes in advanced NSCLC patients treated with EGFR-TKIs.
  • Analysis of existing research data to synthesize findings on the predictive value of EGFR polymorphisms.

Main Results:

  • Emerging evidence suggests that EGFR gene polymorphisms are associated with clinical outcomes and prognosis in advanced NSCLC patients undergoing EGFR-TKI treatment.
  • These polymorphisms may serve as alternative or complementary biomarkers to EGFR mutations for predicting treatment response.

Conclusions:

  • EGFR gene polymorphisms represent a promising area for identifying biomarkers to predict EGFR-TKI efficacy in advanced NSCLC.
  • Further research into EGFR polymorphisms could lead to more personalized and effective treatment strategies for NSCLC patients.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...